Manufacturer assistance programmes and their eligibility rules

Following, with nothing to contribute beyond having asked the same thing elsewhere.

I have no financial interest in anything named in this thread and I want to say so before I comment on manufacturer assistance programmes, because it is the sort of subject where it matters.

The cost of an independent submission is worth stating in these threads, because it is the main reason people do not do it.

Adding the measurement that post #16 says would settle it.

Two people in this thread mean different things by manufacturer assistance programmes and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.

Nothing here is financial advice and none of it is a route to a transaction.

Narrowing post #19, because the general version has more than one answer.

Counterpoint on manufacturer assistance programmes, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.

Where somebody posts a comparison, the useful version states the date, the region and what was included.

I disagree with the framing of manufacturer assistance programmes above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.

The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.

Post #20 answers the question as asked. The question underneath it is different.

Speaking only to manufacturer assistance programmes as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.

I read post #22 twice before replying, because I had assumed the opposite.

The most useful pricing posts here are the ones that show the arithmetic rather than the conclusion.

Sensible. I would want the same detail before I acted on it either.

Pharmacy acquisition cost: a pharmacy pays less than the patient pays, even at insurance rates. That margin is where the pharmacy's costs and profit live.

Practical note on manufacturer assistance programmes: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.

Everything in post #26 holds. The case it does not cover is the one I have.

Manufacturer assistance programmes is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.

Picking up post #28: that is the part I would want checked first.

Insurance tier placement: a compound might be covered but on a higher tier (higher copay). Moving to a lower tier usually requires prior authorization or documented failure of cheaper alternatives.

Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki.

On post #26 — agreed on the reasoning, with one qualification.

On manufacturer assistance programmes, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.

If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.